Andrew Cheng - Feb 1, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President & CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Feb 1, 2023
Transactions value $
-$1,211,020
Form type
4
Date filed
2/3/2023, 04:25 PM
Previous filing
Jan 5, 2023
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $15.4K +25K +6.74% $0.62* 396K Feb 1, 2023 Direct F1
transaction AKRO Common Stock Sale -$721K -14.8K -3.75% $48.57 381K Feb 1, 2023 Direct F1, F2
transaction AKRO Common Stock Sale -$405K -8.16K -2.14% $49.67 373K Feb 1, 2023 Direct F1, F3
transaction AKRO Common Stock Sale -$100K -2K -0.54% $50.14 371K Feb 1, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -25K -13.45% $0.00 161K Feb 1, 2023 Common Stock 25K $0.62 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.03 to $49.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.045 to $50.04, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.06 to $50.31, inclusive.
F5 The options are vested and currently exercisable.